Pfizer Inc. (NYSE:PFE) Shares Bought by Foundations Investment Advisors LLC

Foundations Investment Advisors LLC grew its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 121.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 72,464 shares of the biopharmaceutical company’s stock after buying an additional 39,719 shares during the period. Foundations Investment Advisors LLC’s holdings in Pfizer were worth $3,713,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Saxon Interests Inc. raised its holdings in shares of Pfizer by 12.9% in the third quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock valued at $367,000 after buying an additional 951 shares during the last quarter. Platte River Wealth Advisors LLC raised its holdings in Pfizer by 62.8% during the third quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock worth $556,000 after purchasing an additional 4,905 shares in the last quarter. Accuvest Global Advisors raised its holdings in Pfizer by 16.6% during the third quarter. Accuvest Global Advisors now owns 12,994 shares of the biopharmaceutical company’s stock worth $569,000 after purchasing an additional 1,848 shares in the last quarter. Ledyard National Bank raised its holdings in Pfizer by 0.5% during the third quarter. Ledyard National Bank now owns 364,223 shares of the biopharmaceutical company’s stock worth $15,938,000 after purchasing an additional 1,654 shares in the last quarter. Finally, Oak Asset Management LLC purchased a new position in Pfizer during the third quarter worth about $723,000. 67.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on PFE shares. The Goldman Sachs Group raised shares of Pfizer from a “neutral” rating to a “buy” rating and increased their price target for the stock from $47.00 to $60.00 in a report on Tuesday, December 13th. Barclays cut their price target on shares of Pfizer from $49.00 to $44.00 and set an “equal weight” rating for the company in a report on Wednesday, February 1st. Wells Fargo & Company cut their price target on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating for the company in a report on Friday. StockNews.com initiated coverage on shares of Pfizer in a report on Thursday. They issued a “buy” rating for the company. Finally, JPMorgan Chase & Co. set a $45.00 target price on shares of Pfizer in a report on Monday, February 27th. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $50.38.

Pfizer Stock Down 0.7 %

PFE stock opened at $40.10 on Friday. The company’s 50 day simple moving average is $43.26 and its 200-day simple moving average is $46.03. The firm has a market capitalization of $225.33 billion, a PE ratio of 7.32, a P/E/G ratio of 1.35 and a beta of 0.64. Pfizer Inc. has a 12 month low of $39.23 and a 12 month high of $56.32. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00.

Pfizer (NYSE:PFE – Get Rating) last released its quarterly earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.03 by $0.11. The business had revenue of $24.30 billion for the quarter, compared to analyst estimates of $24.40 billion. Pfizer had a net margin of 31.27% and a return on equity of 42.03%. The company’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.08 earnings per share. Equities analysts expect that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.